Latest Affinity Asset Advisors, LLC Stock Portfolio
$1.94Billion– No. of Holdings #92
Affinity Asset Advisors, LLC Performance:
2026 Q1: 9.21%YTD: 9.21%2025: 46.96%
Performance for 2026 Q1 is 9.21%, and YTD is 9.21%, and 2025 is 46.96%.
About Affinity Asset Advisors, LLC and 13F Hedge Fund Stock Holdings
Affinity Asset Advisors, LLC is a hedge fund based in New York, NY. On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Affinity Asset Advisors, LLC reported an equity portfolio of $1.9 Billions as of 31 Mar, 2026.
The top stock holdings of Affinity Asset Advisors, LLC are , XENE, ERAS. The fund has invested 5.6% of it's portfolio in APOGEE THERAPEUTICS INC and 5% of portfolio in XENON PHARMACEUTICALS INC.
The fund managers got completely rid off VENTYX BIOSCIENCES INC (VTYX), TANGO THERAPEUTICS INC (TNGX) and ARCUS BIOSCIENCES INC (RCUS) stocks. They significantly reduced their stock positions in TAYSHA GENE THERAPIES INC (TSHA), CULLINAN THERAPEUTICS INC (CGEM) and BRIDGEBIO PHARMA INC (BBIO). Affinity Asset Advisors, LLC opened new stock positions in ENLIVEN THERAPEUTICS INC, DAMORA THERAPEUTICS INC (GLTO) and TYRA BIOSCIENCES INC (TYRA). The fund showed a lot of confidence in some stocks as they added substantially to PERSPECTIVE THERAPEUTICS INC, COMPASS PATHWAYS PLC (CMPS) and BELITE BIO INC (BLTE).
The top stock holdings of Affinity Asset Advisors, LLC are , XENE, ERAS. The fund has invested 5.6% of it's portfolio in APOGEE THERAPEUTICS INC and 5% of portfolio in XENON PHARMACEUTICALS INC.
The fund managers got completely rid off VENTYX BIOSCIENCES INC (VTYX), TANGO THERAPEUTICS INC (TNGX) and ARCUS BIOSCIENCES INC (RCUS) stocks. They significantly reduced their stock positions in TAYSHA GENE THERAPIES INC (TSHA), CULLINAN THERAPEUTICS INC (CGEM) and BRIDGEBIO PHARMA INC (BBIO). Affinity Asset Advisors, LLC opened new stock positions in ENLIVEN THERAPEUTICS INC, DAMORA THERAPEUTICS INC (GLTO) and TYRA BIOSCIENCES INC (TYRA). The fund showed a lot of confidence in some stocks as they added substantially to PERSPECTIVE THERAPEUTICS INC, COMPASS PATHWAYS PLC (CMPS) and BELITE BIO INC (BLTE).
Affinity Asset Advisors, LLC Equity Portfolio Value
Last Reported on: 14 May, 2026
Affinity Asset Advisors, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Affinity Asset Advisors, LLC made a return of 9.21% in the last quarter. In trailing 12 months, it's portfolio return was 80.51%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| enliven therapeutics inc | 23,006,600 |
| helix acquisition corp iii | 12,700,000 |
| damora therapeutics inc | 11,655,000 |
| alto neuroscience inc | 11,240,000 |
| tyra biosciences inc | 9,862,710 |
| korro bio inc | 8,002,150 |
| crispr therapeutics ag | 7,135,500 |
| spyglass pharma inc | 6,477,500 |
New stocks bought by Affinity Asset Advisors, LLC
Additions
| Ticker | % Inc. |
|---|---|
| perspective therapeutics inc | 954 |
| cogent biosciences inc | 600 |
| compass pathways plc | 454 |
| eupraxia pharmaceuticals inc | 429 |
| belite bio inc | 225 |
| ascendis pharma a/s | 216 |
| dianthus therapeutics inc | 204 |
| arrowhead pharmaceuticals in | 185 |
Additions to existing portfolio by Affinity Asset Advisors, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| taysha gene therapies inc | -69.7 |
| cullinan therapeutics inc | -59.56 |
| bridgebio pharma inc | -53.12 |
| establishment labs hldgs inc | -50.00 |
| immunovant inc | -50.00 |
| wave life sciences ltd | -48.08 |
| climb bio inc | -46.15 |
| karyopharm therapeutics inc | -43.79 |
Affinity Asset Advisors, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| travere therapeutics inc | -9,989,000 |
| ventyx biosciences inc | -58,555,600 |
| geron corp | -1,980,000 |
| tango therapeutics inc | -8,860,000 |
| arcus biosciences inc | -7,149,000 |
| avadel pharmaceuticals plc | -5,387,500 |
| mersana therapeutics inc | -2,893,000 |
| ultragenyx pharmaceutical in | -1,725,000 |
Affinity Asset Advisors, LLC got rid off the above stocks
Sector Distribution
Affinity Asset Advisors, LLC has about 73.2% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 73.2 |
| Others | 26.8 |
Market Cap. Distribution
Affinity Asset Advisors, LLC has about 15% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- UNALLOCATED
- LARGE-CAP
- SMALL-CAP
- MICRO-CAP
| Category | % |
|---|---|
| MID-CAP | 39.9 |
| UNALLOCATED | 26.8 |
| LARGE-CAP | 15 |
| SMALL-CAP | 11.7 |
| MICRO-CAP | 5.7 |
Stocks belong to which Index?
About 43.4% of the stocks held by Affinity Asset Advisors, LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 56.6 |
| RUSSELL 2000 | 43.4 |
Affinity Asset Advisors, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Affinity Asset Advisors, LLC
Affinity Asset Advisors, LLC has 92 stocks in it's portfolio. About 37.3% of the portfolio is in top 10 stocks. WVE proved to be the most loss making stock for the portfolio. ERAS was the most profitable stock for Affinity Asset Advisors, LLC last quarter.
Last Reported on: 14 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 2.15 | 362,764 | 41,652,600 | reduced | -30.73 | ||
| AGLE | spyre therapeutics inc | 3.33 | 1,279,130 | 64,519,500 | reduced | -10.71 | ||
| ALEC | alector inc | 0.06 | 500,000 | 1,075,000 | new | |||
| ALKS | alkermes plc | 2.46 | 1,350,000 | 47,736,000 | added | 35.00 | ||
| ANAB | anaptysbio inc | 2.69 | 1,409,990 | 52,132,400 | added | 111 | ||
| ARWR | arrowhead pharmaceuticals in | 0.65 | 200,000 | 12,540,000 | added | 185 | ||
| ASND | ascendis pharma a/s | 1.12 | 95,000 | 21,729,400 | added | 216 | ||
| AVTE | jade biosciences inc | 0.46 | 639,956 | 8,991,380 | reduced | -10.49 | ||
| AVTX | avalo therapeutics inc | 1.03 | 1,340,840 | 20,018,700 | added | 27.57 | ||
| BBIO | bridgebio pharma inc | 0.58 | 150,000 | 11,139,000 | reduced | -53.12 | ||
| BLTE | belite bio inc | 0.54 | 65,000 | 10,363,600 | added | 225 | ||
| CELC | celcuity inc | 0.38 | 3,000,000 | 7,314,000 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 0.57 | 781,260 | 11,101,700 | reduced | -59.56 | ||
| CLDX | celldex therapeutics inc new | 0.82 | 500,000 | 15,860,000 | added | 42.86 | ||
| CMPS | compass pathways plc | 0.32 | 1,108,480 | 6,129,910 | added | 454 | ||
| CNTA | centessa pharmaceuticals plc | 2.87 | 1,400,000 | 55,608,000 | added | 133 | ||
| COGT | cogent biosciences inc | 1.49 | 750,000 | 28,867,500 | added | 114 | ||
| COGT | cogent biosciences inc | 0.44 | 7,000,000 | 8,585,500 | added | 600 | ||
| CORT | corcept therapeutics inc | 0.10 | 50,000 | 2,015,500 | new | |||
| CRNX | crinetics pharmaceuticals in | 0.14 | 75,000 | 2,724,000 | unchanged | 0.00 | ||